Status:
COMPLETED
STUDY The Effect of HNF-4A G60D Variant on the In VIVO CYP2D6 Activity By Tolterodine Pharmacokinetic Study
Lead Sponsor:
Inje University
Conditions:
Genotype Guided(HNF4a)
Healthy Subjects
Eligibility:
All Genders
20-65 years
Phase:
PHASE1
Brief Summary
This study was to investigate the pharmacokinetics of tolterodine, substrate of CYP2D6 in healthy subject in relation to the presence of HNF-4A G60D variant.
Detailed Description
After a single oral administration of 2 mg tolterodine in 31 healthy subjects (6 with the heterozygous mutation of HNF-4A G60D vs 25 subjects with wild type of that whose CYP2D6 genotype and gender we...
Eligibility Criteria
Inclusion
- Healthy subject whose HNF4a and CYP2D6 genotype ware determined
Exclusion
- Subject whose HNF4a and CYP2D6 genotype ware not determined
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT01181505
Start Date
January 1 2007
End Date
June 1 2008
Last Update
August 13 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.